alphavirus
singlestrand
rna
virus
envelop
structur
belong
famili
togavirida
certain
alphavirus
associ
pathogen
result
global
fever
epidem
observ
recent
chikungunya
viru
furthermor
semliki
forest
viru
sfv
venezuelan
equin
enceph
vee
viru
identifi
caus
outbreak
febril
ill
central
africa
epidem
hors
human
south
america
respect
despit
potenti
concern
sever
alphavirus
includ
sfv
sindbi
viru
sin
vee
subject
engin
vector
heterolog
gene
express
case
attenu
strain
employ
sever
type
vector
system
engin
three
type
replicationdefici
vector
consist
nake
rna
recombin
particl
layer
dna
vector
figur
applic
nake
rna
vector
involv
use
vitro
transcrib
rna
express
vector
consist
viral
nonstructur
replicas
gene
foreign
gene
interest
downstream
strong
subgenom
promot
product
recombin
particl
requir
cotransfect
vitro
transcrib
rna
express
vector
describ
helper
vector
suppli
viral
structur
gene
mammalian
cell
line
exampl
babi
hamster
kidney
bhk
cell
gener
particl
capabl
one
round
infect
broad
rang
host
cell
due
select
packag
express
vector
rna
viru
product
occur
layer
dna
vector
system
consist
deliveri
dna
vector
provid
foreign
gene
express
cmv
promot
furthermor
engin
vector
addit
subgenom
promot
fulllength
genom
allow
gener
replicationprofici
particl
provid
improv
deliveri
extend
gene
express
alphaviru
vector
describ
take
advantag
extrem
effici
rna
replic
result
rna
copi
rna
molecul
essenti
question
vector
system
use
obvious
replicationprofici
particl
provid
effici
deliveri
suffer
potenti
insuffici
relat
safeti
aspect
although
replicationdefici
particl
provid
higher
level
safeti
still
margin
risk
gener
replicationprofici
particl
nonhomolog
recombin
minim
unwant
recombin
event
split
helper
vector
system
capsid
envelop
gene
express
separ
helper
vector
engin
far
alphavirus
appli
express
number
topolog
differ
recombin
protein
particularli
use
sfv
particl
result
high
express
level
integr
membran
protein
variou
mammalian
host
cell
line
primari
neuron
vivo
vaccin
develop
vector
base
sfv
sin
vee
appli
nake
rna
recombin
viru
particl
layer
dna
vector
context
viral
tumor
antigen
administ
variou
anim
model
elicit
neutral
antibodi
protect
challeng
tumor
cell
lethal
dose
virus
moreov
nonvir
pathogen
subject
vaccin
develop
replicon
particl
deriv
vee
furthermor
demonstr
activ
safe
potent
system
mucos
cellular
adjuv
coadminist
antigen
final
alphavirus
identifi
caus
viral
epidem
anim
human
number
approach
initi
immun
alphavirusbas
infect
review
latest
develop
alphaviru
vector
vaccin
product
summar
due
immunogen
properti
viral
structur
protein
popular
target
alphavirusbas
vaccin
develop
tabl
context
immun
sfv
particl
express
influenza
nucleoprotein
np
elicit
strong
immun
respons
mice
moreov
veebas
express
influenza
hemagglutinin
ha
provid
protect
challeng
viru
chicken
similarli
sfv
particl
express
hiv
envelop
vee
particl
express
hiv
maca
show
humor
ctl
cytotox
tlymphocyt
respons
mice
furthermor
vee
particl
vaccin
express
cluster
iv
swine
influenza
ha
gene
demonstr
protect
challeng
homolog
influenza
viru
likewis
mice
guinea
pig
vaccin
vee
particl
express
ebola
np
gp
respect
provid
protect
challeng
lethal
dose
ebola
viru
attempt
improv
immunogen
vaccin
candid
herp
simplex
viru
type
protein
fuse
subtyp
influenza
ha
respons
tcell
interferongamma
tcell
observ
vaccin
mice
vee
replicon
particl
express
sever
acut
respiratori
syndrom
coronaviru
sarscov
glycoprotein
manag
provid
protect
challeng
lethal
dose
sarscov
vaccin
mice
furthermor
vee
particl
appli
express
glycoprotein
zoonot
pathogen
hendra
viru
hev
nipah
viru
niv
known
caus
fatal
infect
anim
human
immun
result
enhanc
induct
crossreact
neutral
antibodi
anoth
studi
mice
vaccin
dna
plasmid
alphaviru
replicon
express
rift
valley
fever
viru
rvfv
glycoprotein
gn
fuse
complement
protein
immun
gener
neutral
antibodi
provid
protect
challeng
rvfv
suggest
plasmid
dna
alphaviru
replicon
approach
well
combin
dna
primereplicon
boost
strategi
show
great
promis
valid
rvfv
vaccin
develop
combin
approach
includ
plasmid
vaccin
week
follow
replicon
boost
week
combin
vaccin
approach
sfv
dna
vector
recombin
adenoviru
express
classic
swine
fever
viru
csfv
glycoprotein
elicit
higher
titer
neutral
antibodi
pig
challeng
virul
csfv
shimen
strain
symptom
viremia
observ
combin
vaccin
wherea
vaccin
adenoviru
alon
result
viremia
one
pig
five
furthermor
sequenti
immun
sin
vee
replicon
particl
express
type
hiv
envelop
env
trimer
env
protein
adjuv
provid
partial
protect
macaqu
intraven
challeng
high
dose
simianhuman
immunodefici
viru
shiv
administr
could
extend
intramuscular
mucos
deliveri
differ
degre
protect
observ
challeng
shiv
mucos
administr
contrast
intramuscular
vaccin
render
macaqu
complet
resist
shiv
cotton
rat
sin
dna
vector
carri
hemagglutinin
pmsinh
fusion
protein
pmsinhfdu
elicit
neutral
antibodi
mucos
system
antibodysecret
cell
memori
bcell
secret
tcell
prime
pmsinh
provid
protect
challeng
pulmonari
measl
howev
pmsinhfdu
prime
observ
boost
live
measl
viru
vaccin
anoth
studi
chimer
veesin
replicon
particl
appli
express
measl
viru
hemagglutinin
h
fusion
f
protein
elicit
hightit
neutral
antibodi
tcell
macaqu
intraderm
vaccin
protect
rash
viremia
obtain
challeng
wildtyp
measl
viru
month
vaccin
alphavirus
also
subject
develop
smallpox
vaccin
introduct
gene
vee
particl
vaccin
mice
show
protect
immun
furthermor
vaccin
macaqu
elicit
strong
antibodi
respons
capabl
neutral
inhibit
spread
vaccinia
monkey
pox
virus
sinbas
dna
vaccin
develop
rabi
comparison
convent
rabi
dna
vaccin
sin
dna
vaccin
induc
better
humor
cellmedi
immun
respons
immun
mice
show
complet
protect
challeng
cv
rabi
strain
recent
novel
hepat
c
viru
hcv
vaccin
candid
develop
express
part
hcv
nonstructur
protein
nsp
sfv
vector
insert
larg
kb
allow
express
nsp
lead
strong
longlast
tcell
respons
level
tcell
respons
similar
observ
express
immun
demonstr
signific
growth
delay
hcvexpress
tumor
mous
model
anoth
studi
glycoprotein
either
sudan
viru
sudv
ebola
viru
express
vee
replicon
evalu
vaccin
nonhuman
primat
singl
intramuscular
inject
vee
particl
express
sudv
gp
provid
complet
protect
challeng
sudv
cynomolgu
macaqu
howev
veesudv
gp
vaccin
primat
fulli
protect
back
challeng
ebola
viru
hand
coinject
vee
particl
express
sufv
gp
ebola
viru
gp
show
protect
viru
type
recent
vee
replicon
particl
gener
vero
cell
use
express
glycoprotein
bovin
viral
diarrhea
viru
bvdv
vaccin
bvdv
free
calv
iu
iu
respect
result
neutral
antibodi
titer
abl
crossneutr
type
type
bvdv
genotyp
booster
immun
vaccin
higher
dose
significantli
reduc
viralbas
leukopenia
show
protect
clinic
diseas
similarli
vee
replicon
particl
engin
express
dengu
viru
e
antigen
two
configur
subvir
particl
prme
solubl
dimer
immun
macaqu
result
rapid
product
neutral
antibodi
demonstr
protect
challeng
dengu
viru
moreov
tetraval
vee
replicon
particl
vaccin
induc
protect
respons
four
dengu
viru
serotyp
two
immun
administ
six
week
apart
novel
approach
combin
alphaviru
replicon
pseudotyp
baculoviru
context
pseudotyp
baculoviru
vector
contain
hybrid
cm
promot
sfv
replicon
use
express
protein
porcin
reproduct
respiratori
syndrom
viru
prrsv
compar
pseudotyp
baculoviru
vector
carri
cmv
promot
immun
hybrid
cmvsfv
show
induct
strong
antibodi
gener
immun
respons
stronger
one
elicit
cmv
promot
alon
veterinari
medicin
also
gain
alphaviru
vaccin
develop
context
salmonid
alphaviru
sav
replicon
appli
express
infecti
salmon
anemia
viru
isav
hemagglutininesteras
intramuscular
administr
sav
replicon
provid
protect
challeng
isav
atlant
salmon
contrast
intraperiton
inject
success
anoth
studi
dna
vaccin
base
sav
spike
protein
compar
whole
viru
vaccin
atlant
salmon
whole
viru
vaccin
show
superior
immunogen
dna
vaccin
latter
provid
margin
reduct
viral
replic
protect
sav
challeng
differ
control
alphavirusbas
vaccin
develop
also
address
number
infecti
pathogen
tabl
instanc
sfv
vector
employ
express
plasmodium
falciparum
antigen
elicit
immunolog
memori
vaccin
mice
moreov
vaccin
mice
sin
plasmid
dna
vector
carri
mycobacterium
tuberculosi
antigen
provid
strong
immun
result
longterm
protect
tuberculosi
challeng
anoth
approach
use
sfv
dna
replicon
botulinum
neurotoxin
hc
bontahc
gene
provid
antibodi
lymphoprolif
respons
vaccin
balbc
mice
immunogen
enhanc
granulocytemacrophag
colonystimul
factor
gmcsf
coexpress
adjuv
addit
replicationdefici
sfv
particl
use
express
brucella
abortu
translat
initi
factor
immun
balbc
mice
demonstr
signific
level
protect
challeng
virul
b
abortu
strain
similarli
protect
antigen
pa
bacillu
anthraci
express
sin
vector
result
specif
neutral
antibodi
swiss
webster
mice
offer
protect
challeng
lethal
dose
pathogen
bacteria
alphavirus
found
frequent
applic
area
tumor
vaccin
develop
tabl
context
nake
rna
replicationdefici
particl
dna
layer
vector
employ
deliveri
vehicl
instanc
mice
subject
immun
nake
sfv
rna
replicon
carri
lacz
gene
interestingli
singl
inject
rna
present
complet
tumor
protect
furthermor
tumor
administ
two
day
prior
immun
surviv
extend
day
among
dnabas
tumor
vaccin
approach
sin
vector
express
mous
human
tyrosinerel
evalu
mous
melanoma
model
intramuscular
inject
capabl
break
immun
toler
provid
protect
melanoma
mice
vaccin
five
day
prior
cancer
challeng
anoth
studi
alphaviru
repliconbas
express
melanoma
differenti
antigen
mda
tyrosin
demonstr
inhibit
growth
transplant
melanoma
context
vaccin
encod
tyrosin
relat
protein
reli
novel
immun
mechan
requir
activ
igg
cell
effector
respons
furthermor
vaccin
recombin
particl
express
gene
human
papilloma
viru
hpv
gene
sfv
vee
vector
respect
provid
protect
tumor
develop
mice
attempt
also
made
improv
efficaci
sfvbase
hpv
vaccin
suppli
sfvbase
express
mice
low
dose
stimul
antigenspecif
ctl
respons
enhanc
antitumor
respons
sfvbase
immun
subsequ
increas
dosag
howev
neither
improv
immun
respons
tumor
regress
sin
dna
vector
employ
express
murin
melanoma
cell
adhes
molecul
vaccin
murin
melanoma
result
induct
humor
tcell
immun
respons
melanoma
context
breast
cancer
dnabas
sin
vector
express
neu
gene
appli
intramuscular
vaccin
mice
day
prior
inject
cancer
cell
overexpress
neu
immun
provid
strong
protect
tumor
develop
incid
lung
metastasi
mammari
fat
pad
tumor
reduc
moreov
number
lung
metastas
intraven
inject
neu
overexpress
cell
decreas
addit
intraderm
vaccin
provid
tumor
protect
appli
less
plasmid
requir
convent
dna
vector
confirm
success
cancer
vaccin
obtain
administr
sin
vector
express
neu
psincpneu
murin
breast
tumor
model
howev
case
prophylact
vaccin
show
efficaci
administ
prior
tumor
challeng
anoth
approach
compris
combin
alphavirusbas
deliveri
chemic
anticanc
agent
doxorubicin
psincpneu
dna
veeneu
particl
administ
inject
mgkg
doxorubicin
tumor
progress
significantli
delay
phenomenon
occur
doxorubicin
alon
similarli
combin
therapi
paclitaxel
mgkg
psincpneu
ineffect
moreov
veeneu
particl
subcutan
administ
rat
mammari
tumor
model
result
elimin
preexist
aggress
mammari
tumor
combin
dendrit
cell
dc
base
cancer
immunotherapi
veeneu
particl
administr
induc
cellular
humor
immun
neu
transgen
human
breast
tumorbear
mice
moreov
treatment
result
signific
inhibit
tumor
growth
similarli
tumor
growth
pulmonari
metastat
spread
significantli
inhibit
mice
tumor
subject
five
immun
vlp
express
vascular
endotheli
growth
factor
receptor
furthermor
coimmun
sfv
particl
encod
gener
signific
tumor
regress
mice
lung
cancer
also
target
combin
therapi
particl
monoclon
antibodi
syngen
lung
carcinoma
inhibit
intratumor
administr
costimul
mab
context
colon
cancer
vaccin
sinbas
dna
vector
carri
lacz
gene
compar
convent
plasmid
dna
vector
mice
tumor
intramuscular
immun
elicit
immun
respons
dose
lower
sin
dna
replicon
vector
compar
convent
dnalacz
vector
similarli
sfv
particl
provid
express
vaccin
mice
inhibit
colon
carcinoma
growth
closer
analysi
microvessel
densiti
demonstr
signific
inhibit
tumor
angiogenesi
occur
addit
mice
coimmun
particl
surviv
rate
significantli
enhanc
furthermor
oncolyt
sfv
vector
use
immun
stimul
colon
tumor
model
intratumor
inject
led
immedi
intens
inflammatori
reaction
signific
improv
surviv
rate
sfv
particl
express
subject
prophylact
vaccin
develop
murin
model
cervic
cancer
low
dose
particl
result
hpvspecif
ctl
respons
mice
wherea
higher
dose
particl
elicit
ctl
respons
anim
furthermor
dose
particl
mice
protect
tumor
challeng
anoth
studi
particl
vaccin
show
potenti
intraven
intramuscular
deliveri
exponenti
grow
tumor
complet
resolv
similarli
sin
viru
rna
replicon
express
hpv
evalu
mous
model
humor
cellular
immun
respons
poor
tumor
protect
obtain
hpv
gene
fuse
secretori
sig
protein
lysosomeassoci
membran
protein
enhanc
helper
tcell
cytotox
tcell
activ
observ
moreov
strong
vivo
antitumor
activ
induc
anoth
studi
sin
viru
particl
express
hpv
calreticulin
crt
endoplasm
reticulum
bind
transport
test
prophylact
vaccin
vaccin
gener
antigenspecif
immun
respons
effect
strong
antitumor
activ
furthermor
intramuscular
immun
one
week
prior
challeng
carcinoma
cell
provid
protect
treat
mice
also
vee
particl
express
hpv
subcutan
inject
mice
two
week
prior
cancer
cell
inocul
prevent
tumor
format
furthermor
vaccin
induc
longterm
memori
protect
observ
challeng
three
month
immun
therapeut
efficaci
treat
tumorbear
mice
howev
coexpress
hpv
vector
significantli
enhanc
therapeut
effect
prostat
tumor
model
vee
particl
express
human
prostatespecif
membran
antigen
psma
show
strong
cellular
humor
immun
subcutan
administr
furthermor
vee
particl
employ
express
predominantli
prostat
tissuespecif
six
transmembran
epitheli
antigen
prostat
steap
veesteap
particl
induc
specif
immun
respons
significantli
prolong
overal
surviv
mice
bear
tumor
tramp
mice
prophylact
immun
prostat
stem
cell
antigen
psca
dna
plasmid
follow
particl
administr
specif
immun
respons
antitumor
protect
observ
vaccin
anim
sever
vaccin
studi
target
brain
tumor
instanc
sfv
particl
express
endostatin
show
signific
reduct
intratumor
vascular
intratumor
deliveri
anoth
approach
bonemarrow
isol
dendrit
cell
dc
transduc
sfv
vector
carri
cytokin
gene
specif
cdna
melanoma
glioma
cell
prevaccin
dc
transduc
sfvbase
glioma
cdna
respect
result
tumor
challeng
protect
prolong
surviv
tumorbear
mice
combin
dc
transduc
particl
system
administ
also
provid
increas
surviv
rate
moreov
express
human
melanomaassoci
antigen
sin
viru
dna
vector
induc
specif
antitumor
ctl
respons
provid
antitumor
protect
vaccin
prevent
tumor
format
demonstr
signific
prolong
surviv
mice
establish
tumor
alphavirus
suggest
respons
epidem
variou
part
world
also
becom
import
develop
vaccin
alphavirus
tabl
context
protect
airborn
viru
observ
balbc
mice
vaccin
attenu
vee
strain
anoth
studi
improv
protect
vee
challeng
achiev
use
live
attenu
vee
vaccin
similarli
chimer
eastern
equin
enceph
eee
western
equin
enceph
wee
viru
appli
vaccin
mice
complet
protect
observ
lethal
challeng
virul
eastern
equin
enceph
eee
viru
strain
attempt
design
attenu
alphavirus
vaccin
develop
mechan
replic
virushost
interact
investig
context
mosquito
transmiss
chikungunya
chik
viru
prevent
make
replic
depend
intern
ribosom
entri
site
ire
although
replic
occur
mosquito
cell
replic
proce
effici
vero
cell
anoth
approach
nonstructur
gene
attenu
vee
strain
natur
attenu
eev
strain
respect
engin
structur
gene
chik
chimer
vaccin
candid
present
significantli
reduc
infect
common
urban
aed
aegypti
albopictu
vector
chik
therebi
provid
low
risk
viru
transmiss
new
chik
viru
isol
acut
infect
human
patient
use
engin
synthet
dna
vaccin
dna
vaccin
electropor
mice
robust
antigenspecif
cellular
humor
respons
obtain
provid
protect
challeng
chik
furthermor
immun
macaqu
demonstr
induct
neutral
antibodi
similar
elicit
sera
convalesc
human
patient
anoth
dna
vector
approach
vee
structur
gene
express
administ
aerosol
nonhuman
primat
vaccin
result
viremia
two
macaqu
low
viremia
one
anim
wherea
high
control
anim
approach
target
epiderm
dermal
antigen
present
cell
apc
nanopatch
np
technolog
appli
skin
vaccin
west
nile
viru
chik
mice
np
compris
array
dens
pack
project
two
order
magnitud
smaller
standard
needl
provid
effici
deliveri
inactiv
whole
chik
vaccin
dnabas
west
nile
viru
vaccin
moreov
viruslik
particl
vlp
consist
chik
capsid
envelop
protein
demonstr
protect
nonhuman
primat
infect
multipl
strain
chik
benefit
screen
optim
solut
condit
stabl
vaccin
formul
context
sugar
sugar
alcohol
polyanion
identifi
potenti
stabil
rel
recent
discoveri
commonli
occur
phenomenon
gene
silenc
also
made
impact
vaccin
develop
context
small
interf
rna
sirna
engin
two
conserv
region
gene
chik
signific
reduct
viru
titer
observ
vero
cell
h
h
suggest
potenti
new
therapeut
approach
anoth
approach
microrna
mirna
specif
target
sequenc
replicon
particl
product
introduc
alphaviru
helper
rna
presenc
mirnaspecif
inhibitor
chik
particl
effici
gener
wherea
absenc
cellular
mirna
downregul
helper
rna
replic
mice
inocul
replicon
rna
carri
engin
mirna
sequenc
cellular
mirna
prevent
replic
replicon
rna
open
feasibl
use
mirna
therapeut
approach
inhibit
viral
replic
moreov
vee
rnadepend
rna
polymeras
rdrp
target
artifici
mirna
attempt
inhibit
vee
replic
five
mirna
evalu
bhk
cell
three
show
signific
inhibit
vee
replic
despit
larg
number
studi
conduct
variou
anim
model
rel
evalu
subject
human
clinic
trial
conduct
alphavirus
involv
intraven
administr
liposom
encapsul
sfv
particl
express
particl
melanoma
kidney
carcinoma
patient
high
transient
express
recombin
fivefold
increas
last
day
higher
dose
induc
fever
respons
patient
maximum
toler
dose
mtd
restrict
encapsul
particl
per
liposom
sfvrelat
toxic
observ
furthermor
liposomeencapsul
prevent
sfv
particl
recogn
host
immun
system
therefor
allow
repeat
system
administr
phase
studi
clearli
demonstr
safe
administr
encapsul
sfv
particl
human
phase
ii
random
doubleblind
placebocontrol
safeti
immunogen
studi
conduct
healthi
adult
volunt
serial
passag
plaquepurifi
live
chik
vaccin
singl
subcutan
inject
chik
vaccin
administ
volunt
individu
receiv
placebo
advers
event
except
transient
arthralgia
five
individu
receiv
chik
vaccin
evalu
vaccin
individu
develop
chik
neutral
antibodi
day
still
remain
seroposit
one
year
later
none
individu
receiv
placebo
seroposit
anoth
vaccinerel
alphaviru
phase
random
doubleblind
clinic
trial
cytomegaloviru
cmv
twocompon
vaccin
express
cmv
gb
fusion
protein
administ
intramuscularli
subcutan
cmv
seroneg
adult
volunt
vaccin
show
mild
moder
local
reaction
clinic
import
chang
induc
neutral
antibodi
multifunct
tcell
respons
cmv
antigen
anoth
clinic
trial
alphaviru
particl
express
carcinoembryon
antigen
cea
repeatedli
administ
patient
metastat
cancer
ceaspecif
antibodi
abl
mediat
antibodydepend
cellular
cytotox
tumor
cell
human
colorect
cancer
metastas
furthermor
patient
ceaspecif
antibodi
encouragingli
show
extend
overal
surviv
similarli
vee
replicon
express
prostatespecif
membran
antigen
psma
appli
human
trial
patient
metastat
cancer
five
dose
iu
iu
lower
dose
psmaspecif
cellular
respons
obtain
weak
psmaspecif
signal
detect
elisa
disappointingli
higher
dose
show
respons
trial
demonstr
neither
clinic
benefit
robust
immun
respons
toxic
associ
immun
veepmsa
particl
well
toler
howev
neutral
antibodi
elicit
dose
might
suboptim
requir
optim
number
vaccin
develop
studi
conduct
use
mainli
three
commonli
appli
alphaviru
vector
sfv
sin
vee
demonstr
varieti
approach
avail
replicon
particl
nake
rna
layer
dna
vector
employ
approach
commonli
gener
respons
detect
cellular
humor
respons
case
vaccin
develop
lethal
virus
tabl
nonvir
infecti
target
tabl
tumor
tabl
immun
provid
longterm
protect
challeng
diseasecaus
agent
moreov
due
pathogen
sever
alphavirus
credibl
target
vaccin
develop
therefor
number
studi
particularli
vee
chik
tabl
provid
protect
challeng
virul
alphaviru
strain
potenti
alphavirus
caus
global
epidem
place
addit
concern
need
address
biosafeti
issu
gener
strain
use
vaccin
develop
attenu
furthermor
case
use
alphaviru
particl
second
gener
helper
vector
split
helper
system
appli
prevent
product
wildtypelik
replicationprofici
particl
nonhomolog
recombin
recent
alphavirusbas
vaccin
subject
clinic
trial
context
sfv
vector
use
deliveri
immunostimulatori
gene
furthermor
immun
treatment
cmv
vaccin
prostat
metastat
cancer
conduct
alphaviru
vector
particl
strength
appli
alphavirus
gener
rapid
transgen
express
transient
natur
express
howev
full
potenti
alphavirusbas
vaccin
explor
yet
futur
anticip
addit
posit
observ
particularli
form
provid
protect
challeng
lethal
pathogen
tumor
attract
enhanc
applic
alphavirus
vaccin
develop
